Please login to the form below

Not currently logged in
Email:
Password:

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements
EU flag

Three new medicines and six licence extensions have all been recommended for European approval from the CHMP.

The CHMP, the drug safety and efficacy arm of the EMA, has recommended approval for Otsuka's Jinarc (tolvaptan) for the treatment of patients with autosomal dominant polycystic kidney disease (ADPKD), and Sanofi's new insulin Toujeo, the follow up to its blockbuster insulin Lantus.

The CHMP has also recommended granting a conditional marketing authorisation for Novartis' Zykadia (ceritinib).

Specifically, the licence for the drug is for non-small cell lung cancer patients expressing the anaplastic lymphoma kinase (ALK) mutation.

It is designed to treat patients at an advanced stage and in a second-line setting, after patients have already been treated with Pfizer's established ALK lung cancer treatment Xalkori (crizotinib).

The CHMP also made six recommendations on extensions of therapeutic indication.

This includes Adenuric, blockbuster oncology treatment Avastin (bevacizumab) from Roche; AbbVie's auto-inflammatory drug Humira (adalimumab), Menarini's gout drug Adenuric, (febuxostat), the rare disease drug for kidney disease Soliris (eculizumab), BMS's HIV pill Sustiva (efavirenz), and finally Amgen's cancer medicine Vectibix (panitumumab).

Article by
Ben Adams

3rd March 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics